Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CPN1 | P15169 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9261922 | 1.00 | CTSK (0.50) | CTSKCTSSCPN1CPB2GABRB1 | |
| SCHEMBL11065297 | 1.00 | CTSK (0.50) | CTSKCTSSCPN1CPB2GABRB1 | |
| SCHEMBL6546992 | 0.89 | CTSK (0.47) | CTSKCTSSCPN1CPB2GABRB1 | |
| SCHEMBL10093129 | 0.88 | CTSS (0.46) | CTSKCTSSGABRB1GABRB2S1PR3 | |
| SCHEMBL3618570 | 0.88 | CTSS (0.46) | CTSKCTSSGABRB1GABRB2S1PR3 | |
| SCHEMBL27204311 | 0.85 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2ACE | |
| SCHEMBL10891091 | 0.85 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2ACE | |
| SCHEMBL14161705 | 0.85 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2ACE | |
| SCHEMBL31230471 | 0.85 | CTSK (0.51) | CTSKCTSSGABRB1GABRB2ACE | |
| SCHEMBL116386 | 0.84 | CTSK (0.66) | CTSKCTSSGABRB1GABRB2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249291-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | CASMA THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-2349990-B1 | ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE | PIMCO 2664 LTD (GB) | 2018-05-02 | — | — | EP | disclosed |
| US-8207167-B2 | Aryl-phenyl-sulfonamide-phenylene compounds and their use | PIMCO 2664 LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20110190302-A1 | Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| US-5378838-A | FOR USE IN HUMANS | MERCK & CO., INC. (US) | 1995-01-03 | — | — | US | disclosed |
| WO-1994015924-A1 | CHOLECYSTOKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| US-4091227-A | ANTIBACTERIAL AGENTS | SMITHKLINE CORPORATION (US) | 1978-05-23 | — | — | US | disclosed |
| US-4067977-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1978-01-10 | — | — | US | disclosed |
| US-4067976-A | BACTERICIDES | SMITHKLINE CORPORATION (US) | 1978-01-10 | — | — | US | disclosed |
| US-4067978-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1978-01-10 | — | — | US | disclosed |
| US-4007173-A | BACTERICIDE | SMITHKLINE CORPORATION (US) | 1977-02-08 | — | — | US | disclosed |
| US-3988451-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1976-10-26 | — | — | US | disclosed |
| US-3931160-A | BACTERICIDE | SMITHKLINE CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190302-A1 | Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use | SOST, PSAP, ARSA | CTSK 240/4885CTSS 114/4885CPN1 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.